Pathways to Hearing Restoration After Childhood Cancer Treatment: An Expert Analysis

I AM DEAF MYSELF FROM A BRAIN TUMOR BACK WHEN I WAS 4 YEARS OLD, AND I WANT TO PROVIDE A BLOG FOR THOSE WHO MAY HAVE SOME OF THE SAME QUESTIONS I DO ! WHAT THE F***K HAPPENED! 

Introduction: Understanding Treatment-Induced Hearing Loss

This report provides a comprehensive analysis of the auditory challenges resulting from treatments for childhood cancers like medulloblastoma and explores the full spectrum of potential pathways toward hearing restoration. Such treatments, while life-saving, can have significant long-term consequences, including profound hearing loss.

The resulting condition can be medically defined as a profound, bilateral, mixed hearing loss with functional single-sided deafness. This complex diagnosis can be understood by its individual components:

• Bilateral Sensorineural Component: This refers to the damage to the inner ear structures (the cochlea and its sensory hair cells) and the auditory nerves in both ears. This type of damage disrupts the conversion of sound into neural signals.

• Unilateral Conductive Component: This refers to mechanical issues with the outer or middle ear, such as a non-functional eardrum, which prevents sound from being efficiently conducted into the middle ear.

• Functional Single-Sided Deafness (SSD): The combination of these factors can result in a situation where one ear is completely non-functional and the other has severely limited function, often relying on a hearing aid.

The objective of this report is to provide an exhaustive, evidence-based analysis of every potential pathway to restoring some measure of hearing for individuals with this type of complex auditory injury. It will address currently available technologies, their specific applicability to this unique pattern of injury, and the future possibilities emerging from the frontiers of medical research. The central goal is to answer the fundamental question of what possibilities exist for hearing restoration.

Section 1: The Pathophysiology of Treatment-Induced Hearing Loss

To understand the options for restoration, it is first essential to understand the precise nature of the damage to the auditory system. The hearing loss that results is not a single problem but a cascade of injuries resulting directly from the necessary and aggressive treatments used for certain cancers.

1.1 The Auditory System: A Primer

The process of hearing begins when sound waves travel down the ear canal (outer ear) and strike the eardrum (tympanic membrane). The eardrum vibrates, transferring this energy to three tiny bones in the middle ear. These bones amplify the vibrations and transmit them to the cochlea, a fluid-filled, spiral-shaped structure in the inner ear. Inside the cochlea are thousands of microscopic sensory hair cells. The vibrations cause these hair cells to bend, which opens ion channels and converts the mechanical sound energy into electrical signals. These signals are then transmitted via the auditory nerve to the brain, where they are interpreted as sound. Damage at any point in this pathway can cause hearing loss.

1.2 Radiation-Induced Ototoxicity: The Primary Insult

Radiation therapy required to treat certain brain tumors, like medulloblastoma located in the posterior fossa, inevitably exposes the delicate structures of the auditory system to high doses of ionizing radiation. This exposure causes damage through the formation of destructive free radicals and a subsequent inflammatory response, leading to permanent and often progressive cellular injury.

• Sensorineural Damage: The inner ear is highly sensitive to radiation. The damage is multifaceted.

• Cochlear Damage: Radiation is profoundly toxic to the sensory hair cells within the cochlea. It particularly affects the outer hair cells, which are responsible for amplifying and fine-tuning sound, corresponding to the high-frequency hearing loss that is a hallmark of this injury. It also damages the stria vascularis, a critical structure that supplies the metabolic energy required for the cochlea to function. The loss of these cells is irreversible in mammals.

• Auditory Nerve Damage: While the auditory nerve is considered more resistant to radiation than the cochlea, it is not immune. High radiation doses, especially those used in older treatment regimens for brain tumors, can cause direct damage to the nerve itself, impairing its ability to transmit electrical signals to the brain. This point is of paramount importance when considering implantable hearing devices.

• Conductive Damage: Radiation can also cause problems in the outer and middle ear. It can lead to chronic fluid buildup (otitis media with effusion), thickening and scarring of the eardrum, and in some cases, necrosis (death) of the small hearing bones. This provides a direct biological explanation for the failure of an eardrum.

1.3 Chemotherapy-Induced Ototoxicity: A Compounding Factor

It is highly probable that a treatment regimen for medulloblastoma also included a platinum-based chemotherapy agent, most commonly cisplatin, which was a cornerstone of therapy. Cisplatin is notoriously ototoxic, independently causing permanent, dose-dependent sensorineural hearing loss by damaging the same inner ear hair cells targeted by radiation.

Crucially, radiation and cisplatin have a synergistic effect, meaning their combined toxicity is greater than the sum of their individual effects. Radiation significantly potentiates, or amplifies, the damage caused by cisplatin. Consequently, the dose of radiation required to cause severe hearing loss is much lower when administered alongside cisplatin. This combination therapy, while effective against the cancer, created a "perfect storm" of ototoxicity, leading to the profound level of hearing loss experienced by many survivors of that treatment era.

1.4 The Medulloblastoma Context: A Known Late Effect

The hearing loss described is a well-documented and tragic outcome for many childhood medulloblastoma survivors, particularly those treated before the advent of more modern techniques. Studies confirm high rates of severe ototoxicity, with a significant percentage of survivors requiring hearing aids or experiencing profound deafness.

This connection is so well-established that the medical field has actively worked to mitigate these effects. The severe late effects experienced by this generation of survivors are the primary reason that modern oncology protocols have evolved. Current clinical trials actively investigate the use of otoprotective drugs like sodium thiosulfate, which is administered with cisplatin specifically to prevent hearing loss. Furthermore, radiation techniques have been refined, with methods like Intensity-Modulated Radiation Therapy (IMRT) and proton beam therapy now used to shape the radiation field more precisely, sparing the cochlea and other critical structures whenever possible. This evolution of care is a direct response to the long-term challenges faced by survivors.

Section 2: Addressing the Conductive Component: Eardrum Repair

This section focuses on the mechanical problems that can arise, such as a non-functional eardrum. It is essential to approach this issue with a clear understanding of what can and cannot be achieved through surgical repair.

2.1 Understanding a Non-Functional Eardrum

The eardrum, or tympanic membrane, acts as the first critical link in the mechanical chain of hearing. Its primary job is to vibrate in response to sound waves, transmitting that energy to the bones of the middle ear. A large perforation or a non-functional, scarred eardrum breaks this chain, causing a significant conductive hearing loss. This type of loss can account for a hearing deficit of up to 40–60 decibels (dB). In cases of combined damage, this conductive loss is layered on top of pre-existing profound sensorineural damage. While traumatic perforations can sometimes heal on their own, chronic perforations, especially those in an irradiated field, often require surgical intervention.

2.2 Tympanoplasty: The Surgical Solution

The standard surgical procedure to repair a damaged eardrum is called tympanoplasty. During this procedure, a surgeon uses a graft—typically a small piece of the patient's own tissue harvested from the fascia (a thin layer of connective tissue) over the temple muscle or cartilage from the outer ear—to patch the hole. This surgery is performed with high precision using an operating microscope or an endoscope and can be approached either through the ear canal or via a small, hidden incision behind the ear.

The use of autologous grafts (tissue from one's own body) is the gold standard, as it ensures biocompatibility and minimizes risks of rejection or disease transmission. The success rate for anatomically closing the perforation with tympanoplasty is very high, often exceeding 90%.

2.3 Managing Expectations: The Goal of Tympanoplasty in Combined-Damage Scenarios

It is absolutely critical to establish realistic expectations for a tympanoplasty in this context. While the surgery has a high success rate in repairing the physical hole in the eardrum, it will not restore functional hearing to an ear with profound underlying nerve damage.

The reason for this is fundamental to the dual nature of the injury. Tympanoplasty can only fix the conductive (mechanical) part of the hearing loss. It cannot address the profound, irreversible sensorineural (nerve) damage caused by radiation and chemotherapy. Even with a perfectly reconstructed eardrum, if the inner ear and auditory nerve cannot process sound into a neural signal, no hearing will occur.

Therefore, the primary goals of considering a tympanoplasty would be:

1. To restore the anatomical integrity of the ear, creating a closed, healthy middle ear space.

2. To prevent potential complications, such as recurrent ear infections and drainage (otorrhea), which can occur with an open perforation.

3. To potentially prepare the ear for other advanced interventions, should they be deemed an option after a full evaluation.

The decision to proceed with this surgery should be seen as a step toward restoring the health of the ear, not the function of hearing.

Section 3: Bypassing the Damage: A Deep Dive into Implantable Hearing Solutions

Given that conventional hearing aids provide limited benefit in many cases, the most viable pathways to significant auditory restoration involve advanced implantable technologies. These devices are designed to bypass the damaged parts of the auditory system. The choice among them is not a matter of preference but is dictated by a rigorous diagnostic evaluation that determines which parts of the auditory pathway remain functional.

3.1 The Central Question: Assessing Auditory Nerve Viability

The single most important factor that will determine the available options is the functional status of the cochleae and, most critically, the auditory nerves. Before any implant can be considered, a comprehensive evaluation is necessary to answer one question: can the auditory nerves still carry an electrical signal to the brain? This evaluation typically includes :

• High-Resolution Imaging: A CT scan of the temporal bones and a high-resolution MRI of the brain and internal auditory canals are used to visualize the physical structures of the inner ear and the auditory nerves. This can reveal if the nerves are present, if they are abnormally small (hypoplastic), or if there are other anatomical issues.

• Electrophysiological Testing: An Auditory Brainstem Response (ABR) test measures the brain's electrical activity in response to sound. An absent ABR signal indicates a severe disruption somewhere along the auditory pathway from the cochlea to the brainstem.

• Promontory Stimulation: In some cases, a test called promontory stimulation may be performed. A tiny electrode is placed near the cochlea, and a small electrical current is applied. If a sound is perceived, it suggests the auditory nerve is at least partially functional and capable of transmitting a signal. An absent response implies severe nerve damage.

The results of these tests create a "diagnostic funnel," guiding the decision toward the most appropriate technology. The options represent a clear continuum of intervention, each designed to bypass an increasing level of damage. A hearing aid amplifies sound for a damaged but partially working system. A BAHS reroutes sound to a functional inner ear. A cochlear implant replaces the function of the cochlea to stimulate a working nerve. An Auditory Brainstem Implant replaces the function of both the cochlea and the nerve to stimulate the brainstem directly. The evaluation will determine where on this continuum the best solution lies.

3.2 Option 1: Bone-Anchored Hearing System (BAHS / BAHA)

• How it Works: A BAHS is a specialized device designed to treat conductive hearing loss or single-sided deafness (SSD). It consists of a small titanium implant placed in the skull bone behind the ear and an external sound processor. The processor captures sound, converts it into vibrations, and transmits these vibrations through the skull bone directly to a functioning inner ear (cochlea).

• Candidacy and Application: This is a highly relevant option for functional SSD. The implant is placed on the side of the deaf ear. The sound processor on that side captures sound, and the vibrations travel across the skull to be picked up and processed by the other inner ear. This does not make the deaf ear "hear," but it effectively restores 360-degree sound awareness, eliminates the head shadow effect (where the head blocks sound from reaching the good ear), and can significantly improve understanding in noisy environments.

• Prerequisites and Limitations: The viability of this option depends entirely on the level of residual function in the contralateral cochlea and auditory nerve. The fact that an ear derives benefit from a conventional hearing aid is a strong indicator that there is sufficient function for a BAHS to be successful. Success rates for BAHS in treating SSD are very high, often over 90%, with high patient satisfaction.

3.3 Option 2: Cochlear Implant (CI)

• How it Works: A cochlear implant is a neuroprosthetic device that bypasses the damaged sensory hair cells of the inner ear. It consists of an external processor that captures sound and an internal implant with a fine electrode array that is surgically threaded into the cochlea. This array directly stimulates the auditory nerve endings with electrical pulses, which the brain interprets as sound.

• Candidacy and a Critical Contraindication: A CI is the standard of care for individuals with severe-to-profound sensorineural hearing loss. However, it has one absolute prerequisite: a viable auditory nerve that can transmit the electrical signals to the brain. Medical and insurance guidelines explicitly list lesions in the auditory nerve or central auditory pathway as a contraindication for cochlear implantation. Given the history of high-dose radiation to the posterior fossa, significant damage to the auditory nerves is highly probable. If the nerve is non-functional, the CI will fail, as there is no "wire" to carry the signal from the implant to the brain. Therefore, while a CI must be considered in the evaluation, it is unlikely to be a viable option in cases of known nerve damage.

3.4 Option 3: Auditory Brainstem Implant (ABI)

• The Technology of Last Resort: The ABI is a specialized neuroprosthetic developed for individuals who are profoundly deaf and cannot benefit from a CI because their auditory nerves are absent or non-functional. This profile may align with the condition of an ear after extensive radiation damage.

• How it Works: The ABI bypasses the cochlea and the auditory nerve entirely. It involves a neurosurgical procedure to place a small paddle of electrodes directly onto the surface of the cochlear nucleus in the brainstem—the first auditory processing center in the brain. An external processor, similar to that of a CI, sends coded electrical signals to these electrodes, directly stimulating the brainstem.

• Candidacy and the Non-NF2 Indication: Historically, the ABI was approved by the FDA in the United States only for patients aged 12 and older with a genetic condition called Neurofibromatosis Type 2 (NF2), who lose their auditory nerves during tumor removal surgery. However, this is a rapidly evolving field. There is a growing body of research and several active clinical trials at major academic centers exploring the ABI's use in "non-tumor" patients with other causes of auditory nerve failure, such as trauma, severe inner ear malformations, or post-radiation damage. Candidacy would place an individual at the intersection of established clinical practice and cutting-edge clinical research, likely within the context of such a trial or a specialized off-label program.

• Outcomes and Expectations: ABI outcomes are more variable and generally more modest than CI outcomes. It is crucial to have realistic expectations:

• Universal Benefit: Almost all ABI users gain an awareness of environmental sounds (e.g., alarms, doorbells, approaching traffic), which provides significant safety and quality-of-life improvements.

• Common Benefit: The majority of users find that the sound provided by the ABI serves as a powerful aid to lip-reading, significantly improving speech comprehension in face-to-face conversations.

• Less Common Benefit: A smaller subset of users, particularly in the non-tumor population, achieve some level of "open-set" speech recognition (understanding some speech without visual cues). Telephone use is possible but rare.

• Risks and Commitment: ABI placement is a major neurosurgical procedure that requires a highly specialized, multidisciplinary team of neurotologists, neurosurgeons, and audiologists. The post-operative commitment is substantial, involving extensive auditory rehabilitation to learn how to interpret the "unnatural" quality of the sound produced by direct brainstem stimulation.

Section 4: The Horizon of Hearing Restoration: Regenerative Medicine

While implantable devices bypass damage, the ultimate goal of hearing research is biological restoration: to repair or regrow the damaged parts of the inner ear. This field, known as regenerative medicine, holds immense promise but is still largely in the experimental stages. It is important to view these developments with both excitement for the future and a realistic understanding of the current timeline and challenges.

4.1 The "Holy Grail": Regenerating Damaged Cells

The central challenge in treating sensorineural hearing loss is that the sensory hair cells and neurons of the mammalian inner ear do not regenerate on their own after they are damaged or die. Regenerative medicine seeks to overcome this limitation by using gene therapy or stem cell therapy to induce the creation of new, functional auditory cells.

4.2 Gene Therapy: Reprogramming for Regeneration

Gene therapy aims to introduce new genetic instructions into the remaining, non-sensory cells of the inner ear (such as supporting cells) to reprogram them to become new hair cells.

• Current Research: Scientists have identified key genetic pathways (like Notch and Wnt) and master-switch genes (like ATOH1) that control hair cell development. Research has focused on developing "drug-like cocktails" or using harmless viral vectors to deliver these genetic instructions into the cochlea.

• Clinical Trials and Limitations: The most dramatic recent successes in human gene therapy for hearing have been in treating rare forms of hereditary deafness, such as those caused by mutations in the OTOF gene. In these cases, the therapy provides a working copy of a single missing protein to cells that are otherwise healthy and properly structured. This is a fundamentally different and simpler task than repairing the widespread cellular destruction caused by radiation. An early clinical trial using the gene ATOH1 to regenerate hair cells in patients with acquired hearing loss did not show significant hearing improvement, underscoring the complexity of true regeneration.

• Relevance to Complex Post-Treatment Damage: The nature of the injury—widespread damage to multiple cell types, including hair cells, supporting cells, and neurons, plus scarring—presents a significant hurdle for current gene therapy approaches. A therapy that only regenerates hair cells would likely fail if the auditory neurons they need to connect with are also damaged or absent. The challenge is not just to make new parts, but to rebuild an integrated system.

4.3 Stem Cell Therapy: Rebuilding from Scratch

Stem cell therapy represents an even more ambitious approach. The goal is to use stem cells—either harvested from an external source (exogenous) or by activating dormant progenitor cells already in the ear (endogenous)—to grow entirely new hair cells and, critically, the auditory neurons (spiral ganglion cells) they connect to.

• Current Research: Researchers are working with various types of stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), to learn how to guide their differentiation into the specific cell types of the inner ear. Some early-phase clinical trials have explored using small-molecule drugs to activate the inner ear's own progenitor cells, with some initial promising results in patients with noise-induced or sudden hearing loss.

• Challenges: The path to clinical application is long. Major scientific challenges remain, including ensuring the stem cells survive transplantation, differentiate into the correct cell types, migrate to the right locations within the intricate 3D structure of the cochlea, form precise synaptic connections with each other, and, most importantly, do not form tumors.

For conditions involving extensive damage from radiation, a future "cure" will likely require not one, but a combination of these advanced biological approaches. One can envision a multi-stage therapy decades from now that might first use biological agents to clear scar tissue, then use stem cells to regrow the basic cellular architecture of the cochlea, and finally use gene therapy to guide the new cells to form the correct, functional neural connections. This is the logical, albeit distant, endpoint of current research trajectories.

Section 5: Charting a Path Forward: A Roadmap for Evaluation and Action

The information presented in this report leads to a clear, actionable path forward. The journey from profound hearing loss to potential restoration begins not with a choice of treatment, but with a definitive diagnostic evaluation at a specialized medical center.

5.1 Step 1: Comprehensive Diagnostic Evaluation

The mandatory and non-negotiable first step is a comprehensive diagnostic evaluation. A piecemeal evaluation will not suffice. A complete workup from a multidisciplinary team at a major medical center is required to fully characterize the state of the auditory system. This evaluation must include:

• Complete Audiological Assessment: This goes beyond a standard hearing test. It must include pure-tone audiometry for both air and bone conduction, detailed speech recognition testing (with and without hearing aids), and tympanometry to assess middle ear function.

• High-Resolution Imaging: Both a high-resolution Computed Tomography (CT) scan of the temporal bones and a high-field Magnetic Resonance Imaging (MRI) scan of the internal auditory canals and brainstem are essential. This imaging will provide a detailed anatomical map of the cochleae and, most importantly, will visualize the auditory nerves to assess their size and integrity.

• Electrophysiological Testing: An Auditory Brainstem Response (ABR) test is critical to measure the functional integrity of the entire auditory pathway. The presence or absence of a neural response to sound provides objective data on nerve function.

• Otolaryngology/Neurotology Consultation: A physical examination and review of all data by a neurotologist—an ENT subspecialist who focuses on complex disorders of the ear and skull base—is necessary to synthesize the findings.

5.2 Step 2: Identifying a Center of Excellence

Complex cases like these require a rare convergence of multiple specialties. The ideal institution is a major academic medical center that has nationally recognized, top-tier programs in:

• Otology, Neurotology, and Skull Base Surgery: This ensures access to the surgical expertise required for advanced implantable devices like the BAHS and, especially, the ABI.

• A Long-Term Childhood Cancer Survivor Program: These programs specialize in managing the complex, lifelong health issues that arise from pediatric cancer treatments. They have deep expertise in the specific patterns of late effects caused by therapies like radiation and chemotherapy.

• A Multidisciplinary Team Approach: The best centers operate with collaborative teams where neurotologists, neurosurgeons, audiologists, radiologists, and survivorship specialists work together to formulate a single, comprehensive treatment plan.

Based on national rankings and published research, institutions with strong programs in these intersecting fields include, but are not limited to: Mayo Clinic , Johns Hopkins Medicine , NYU Langone Health , Stanford Health Care , Mass Eye and Ear (part of Mass General Brigham) , and other leading centers with top-ranked neurosurgery and ENT departments.

5.3 Step 3: Navigating the Consultation and Clinical Trials

Once an appointment is secured, preparation is the next step. It is vital to gather and provide the medical center with all past medical records, including the original pathology reports for the cancer, detailed summaries of the radiation therapy (including total dose and fields), and records of the chemotherapy regimen.

The goal of the consultation will be to use the results of the new diagnostic evaluation to determine the most viable path forward. The discussion will likely center on the risks and benefits of a BAHS versus a potential ABI. If an ABI is deemed a possibility, it will almost certainly be in the context of a clinical trial for non-NF2 patients. Resources like ClinicalTrials.gov can be used to identify active trials (e.g., NCT01864291, NCT01736267, NCT02310399) and the centers conducting them. Engaging in a clinical trial is a significant decision that involves a thorough informed consent process and a partnership with the research team.

Conclusion: A Realistic Perspective on Hope and Action

In summary, the question of whether hearing can be restored after aggressive cancer treatment is complex, with no simple answer. A complete return to normal, effortless hearing is not possible with any current or near-future technology. The damage caused by the life-saving treatments of the past can be too profound.

However, this does not mean there is no hope. On the contrary, there are tangible, realistic, and technologically advanced pathways that could potentially restore a significant degree of sound perception and awareness, fundamentally changing an individual's connection to the world. The analysis indicates two primary avenues for exploration:

1. A Bone-Anchored Hearing System (BAHS) is a realistic, standard-of-care option that could restore 360-degree sound perception by routing sound from a deaf side to a better-functioning inner ear. This is contingent on the better ear having sufficient residual function.

2. An Auditory Brainstem Implant (ABI) represents a more profound intervention. It is an investigational path for this specific condition but offers the potential to restore a sense of hearing directly to the brain, bypassing damaged nerves entirely. This is a complex neurosurgical procedure with variable outcomes, reserved for cases where the auditory nerves are confirmed to be non-functional.

The futuristic promise of regenerative medicine offers a different kind of hope—a long-term vision of biological repair—but it is not a solution for today.

The path forward begins with a single, definitive action: pursuing a comprehensive evaluation at a center of excellence. This step will finally and fully characterize the extent of the damage and, in doing so, will move beyond speculation and illuminate the true, concrete possibilities for the future.

Works cited

1. Core deficits and quality of survival after childhood medulloblastoma ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC6655396/ 2. Hearing after nasopharyngeal cancer treatment, https://www.cancerresearchuk.org/about-cancer/nasopharyngeal-cancer/living-with/hearing 3. Challenges of Hearing Rehabilitation after Radiation and ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC6438801/ 4. Synopsis of Causation Conductive Hearing Loss - GOV.UK, https://assets.publishing.service.gov.uk/media/5a7efa3440f0b6230268cba5/conductive_hearing_loss.pdf 5. Effects of Radiotherapy on Auditory and Vestibular Function - An International Journal of Otorhinolaryngology Clinics, https://www.aijoc.com/journal/AIJOC/effects-of-radiotherapy-on-auditory-and-vestibular-function-10.5005_aijoc-6-4-1/full 6. Managing Radiation-Induced Hearing Loss - Number Analytics, https://www.numberanalytics.com/blog/radiation-induced-hearing-loss-management 7. Mechanism and Protection of Radiotherapy Induced Sensorineural Hearing Loss for Head and Neck Cancer - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC8714384/ 8. A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Fred Hutchinson Cancer Center, https://www.fredhutch.org/en/research/clinical-trials/trial-details.fh_trial_id_14754.a-study-of-treatment-for-medulloblastoma-using-sodium-thiosulfate-to-reduce-hearing-loss.html 9. Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review - PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC4118158/ 10. Medulloblastoma: A report of a rare case with audiological evaluation, https://www.rehabilitationjournals.com/speech-and-audiology-journal/article/65/6-1-1-494.pdf 11. UCSF Medulloblastoma Clinical Trials — San Francisco Bay Area, https://clinicaltrials.ucsf.edu/medulloblastoma 12. A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss, https://research-studies.allinforhealth.info/us/en/listing/12372/a-study-of-treatment/ 13. ACNS2031: A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss - Cincinnati Children's Hospital, https://www.cincinnatichildrens.org/service/c/clinical-trials/studies/ACNS2031 14. Determinants of Hearing Loss in Perforations of the Tympanic Membrane - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC2918411/ 15. Tympanoplasty - StatPearls - NCBI Bookshelf, https://www.ncbi.nlm.nih.gov/books/NBK565863/ 16. Tympanoplasty (Eardrum Reconstruction) | Penn Medicine, https://www.pennmedicine.org/treatments/tympanoplasty-eardrum-reconstruction 17. Tympanoplasty | Johns Hopkins Medicine, https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/tympanoplasty 18. Mixed Hearing Loss | Hearing Loss | Audiology & Hearing Health, https://www.audiologyandhearing.com/resources/hearing-loss/mixed-hearing-loss/ 19. Auditory Brainstem Implantation: An Overview - PMC - PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC6438789/ 20. Auditory Brainstem Implantation - Barrow Neurological Institute, https://www.barrowneuro.org/for-physicians-researchers/education/grand-rounds-publications-media/barrow-quarterly/volume-20-no-4-2004/auditory-brainstem-implantation/ 21. Bone-Anchored Hearing Aids (BAHA) - the Minnesota Department of Human Services (DHS) website, https://www.dhs.state.mn.us/main/idcplg?IdcService=GET_DYNAMIC_CONVERSION&dID=144119 22. Bone-Anchored Hearing Aids (BAHA) - Cleveland Clinic, https://my.clevelandclinic.org/health/treatments/14794-bone-anchored-auditory-implant 23. Cochlear Baha System | Bone Anchored Hearing Solutions, https://www.cochlear.com/us/en/home/products-and-accessories/cochlear-baha-system 24. Cochlear implant candidacy criteria | Adults and children, https://www.cochlear.com/us/en/professionals/products-and-candidacy/candidacy/cochlear-implant 25. CG-SURG-81 Cochlear Implants and Auditory Brainstem Implants, https://www.anthem.com/medpolicies/abc/active/gl_pw_d083867.html 26. Are You a Candidate for Cochlear Implants? - Rocky Mountain Ear Center, https://rockymountainearcenter.com/hearing-aids/are-you-a-candidate-for-cochlear-implants/ 27. 481 Auditory Brainstem Implant, https://www.bluecrossma.org/medical-policies/sites/g/files/csphws2091/files/acquiadam-assets/481%20Auditory%20Brainstem%20Implant%20prn.pdf 28. Auditory Brainstem Implant (ABI) in Pediatric Non-Neurofibromatosis Type 2 Subjects, https://clinicaltrials.gov/study/NCT01864291 29. Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects, https://clinicaltrials.gov/study/NCT01736267 30. Auditory Brainstem Implant Candidacy in the United States in Children 0-17 Years Old, https://pmc.ncbi.nlm.nih.gov/articles/PMC4477282/ 31. Ten-year follow-up of auditory brainstem implants: From intra-operative electrical auditory brainstem responses to perceptual results | PLOS One, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0282261 32. Mass Eye and Ear Hearing Scientists Use Drug-like Cocktail to Regenerate Hair Cells in Preclinical Study, https://masseyeandear.org/news/press-releases/2023/04/mass-eye-and-ear-hearing-scientists-use-drug-like-cocktail-to-regenerate-hair-cells 33. Stem Cell-Based Therapies in Hearing Loss - Frontiers, https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.730042/full 34. Scientists Regenerate Hair Cells that Enable Hearing - Harvard Medical School, https://hms.harvard.edu/news/scientists-regenerate-hair-cells-enable-hearing 35. Gene therapy advancements for the treatment of acquired ... - Frontiers, https://www.frontiersin.org/journals/audiology-and-otology/articles/10.3389/fauot.2024.1423853/full 36. Restoring hearing loss through regenerative medicine | Harvard Stem Cell Institute (HSCI), https://www.hsci.harvard.edu/news/restoring-hearing-loss-through-regenerative-medicine 37. What You Need to Know About Mixed Hearing Loss - Hoffmann Audiology, https://hoffmannaudiology.com/blog/mixed-hearing-loss 38. Otology and Neurotology | Johns Hopkins Otolaryngology – Head and Neck Surgery, https://www.hopkinsmedicine.org/otolaryngology/specialty-areas/otology 39. Anterior Skull Base Surgery Center - NYU Langone Health, https://nyulangone.org/care-services/anterior-skull-base-surgery-center 40. Skull Base Center | MUSC Health | Charleston SC, https://muschealth.org/medical-services/neurosciences/skull-base 41. Top Specialized Hospitals - Neurosurgery - Newsweek Rankings, https://rankings.newsweek.com/worlds-best-specialized-hospitals-2023/neurosurgery 42. Skull Base Surgery Center | Tampa General Hospital, https://www.tgh.org/institutes-and-services/ent-institute/skull-base-surgery-center 43. Skull Base Surgery Center NYC | Mount Sinai - New York, https://www.mountsinai.org/locations/skull-base-surgery-center 44. Long-term Survivor Program - Texas Children's Hospital, https://www.texaschildrens.org/departments/long-term-survivor-program 45. Childhood Cancer Survivorship Program | Mays Cancer Center, https://cancer.uthscsa.edu/cancer-care/programs/childhood-cancer-survivor-program 46. The Long-Term Follow-Up Study (LTFU) | St. Jude Research, https://www.stjude.org/research/departments/epidemiology-cancer-control/surviving-childhood-cancer.html 47. Hearing Loss Specialists and Care Centers | Northwestern Medicine, https://www.nm.org/conditions-and-care-areas/ent-ear-nose-throat/hearing-loss/specialists-and-care-centers 48. Hearing loss - Care at Mayo Clinic, https://www.mayoclinic.org/diseases-conditions/hearing-loss/care-at-mayo-clinic/mac-20373083 49. Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves | ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT02310399 50. Hearing Loss Program | Stanford Health Care, https://stanfordhealthcare.org/medical-clinics/hearing-loss.html 51. Stanford Initiative to Cure Hearing Loss, https://med.stanford.edu/hearinglosscure.html 52. New Auditory Brainstem Implant Shows Early Promise | Mass General Brigham, https://www.massgeneralbrigham.org/en/about/newsroom/articles/new-auditory-brainstem-implant-shows-promise